S P M Drugs Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
- Paid Up Capital ₹ 1.24 M
- Company Age 36 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.10 M
- Revenue Growth 7.49%
- Profit Growth 16.71%
- Ebitda 92.46%
- Net Worth 14.94%
- Total Assets 17.82%
About S P M Drugs
S P M Drugs Private Limited (SPMDPL) is a Private Limited Indian Non-Government Company incorporated in India on 16 June 1988 and has a history of 36 years and seven months. Its registered office is in Erode, Tamil Nadu, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.24 M.
The company currently has active open charges totaling ₹1.10 M.
Vikram Jain and Pankajkumar Jain serve as directors at the Company.
Company Details
-
Location
Erode, Tamil Nadu, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U26916TZ1988PTC002198
-
Company No.
002198
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
16 Jun 1988
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Coimbatore
Industry
Who are the key members and board of directors at S P M Drugs?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vikram Jain
|
Managing Director | 01-Oct-2007 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Pankajkumar Jain
|
Whole-Time Director | 01-Oct-2007 | Current |
Financial Performance of S P M Drugs.
S P M Drugs Private Limited, for the financial year ended 2020, experienced modest growth in revenue, with a 7.49% increase. The company also saw a substantial improvement in profitability, with a 16.71% increase in profit. The company's net worth Soared by an impressive increase of 14.94%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of S P M Drugs?
In 2019, S P M Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹1.10 M
₹0
Charges Breakdown by Lending Institutions
- Karnataka Bank Ltd. : 0.09 Cr
- The Tamilnadu Industrial Investment Corp. Ltd. : 0.02 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 28 Apr 2023 | Karnataka Bank Ltd. | ₹0.93 M | Open |
| 09 Jul 2002 | The Tamilnadu Industrial Investment Corp. Ltd. | ₹0.17 M | Open |
How Many Employees Work at S P M Drugs?
Unlock and access historical data on people associated with S P M Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of S P M Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped S P M Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
